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Abstract
The COVID-19 pandemic has affected how clinical trials are managed, both within existing portfolios and for the
rapidly developed COVID-19 trials. Sponsors or delegated organisations responsible for monitoring trials have
needed to consider and implement alternative ways of working due to the national infection risk necessitating
restricted movement of staff and public, reduced clinical staff resource as research staff moved to clinical areas, and
amended working arrangements for sponsor and sponsor delegates as staff moved to working from home.
Organisations have often worked in isolation to fast track mitigations required for the conduct of clinical trials
during the pandemic; this paper describes many of the learnings from a group of monitoring leads based in United
Kingdom Clinical Research Collaboration (UKCRC) Clinical Trials Unit (CTUs) within the UK.
The UKCRC Monitoring Task and Finish Group, comprising monitoring leads from 9 CTUs, met repeatedly to identify
how COVID-19 had affected clinical trial monitoring. Informed consent is included as a specific issue within this
paper, as review of completed consent documentation is often required within trial monitoring plans (TMPs).
Monitoring is defined as involving on-site monitoring, central monitoring or/and remote monitoring.
Monitoring, required to protect the safety of the patients and the integrity of the trial and ensure the protocol is
followed, is often best done by a combination of central, remote and on-site monitoring. However, if on-site
monitoring is not possible, workable solutions can be found using only central or central and remote monitoring.
eConsent, consent by a third person, or via remote means is plausible. Minimising datasets to the critical data
reduces workload for sites and CTU staff. Home working caused by COVID-19 has made electronic trial master files
(TMFs) more inviting. Allowing sites to book and attend protocol training at a time convenient to them has been
successful and worth pursuing for trials with many sites in the future.
The arrival of COVID-19 in the UK has forced consideration of and changes to how clinical trials are conducted in
relation to monitoring. Some developed practices will be useful in other pandemics and others should be
incorporated into regular use.
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Background
Monitoring is used within clinical trials to protect the
rights and well-being of participants; to ensure data are
accurate, complete and verifiable; and to confirm that
the trial is being run in accordance with the protocol,
with the principles of good clinical practice (GCP) and
with the relevant regulatory requirements [1, 2]. The
type of monitoring conducted by CTUs for a particular
trial is determined by a risk assessment [3] and sum-
marised in a trial monitoring plan.
Risk-based monitoring is often advocated [1, 4, 5].
Rather than monitoring routinely throughout the trial,
the monitoring is directed at pre-defined risks to the
trial, and to risks which become apparent during the ac-
tive phase. The Medicines and Healthcare Products
Regulatory Agency (MHRA) and others have published
guidance on risk-proportionate approaches [6].
In March 2020, the COVID-19 pandemic had a global
impact. Trialists in the UK had to adapt and define new
ways of working. Whilst some academic sponsors had
pandemic/epidemic standard operating procedures
(SOPs) in place, none had been used in practice.
COVID-19 trials were designed and opened at a fast rate
with RECOVERY-RS trial (ISRCTN16912075) [7]
recruiting the first patient just 10 days after the draft
protocol. As other areas of trial conduct have had to
adapt to the pandemic, so has monitoring. Two practical
aspects of the pandemic are that, in order to restrict the
spread of COVID-19, non-essential staff were not per-
mitted within the hospital and research staff within hos-
pitals were redeployed to ensure clinical care was
prioritised. This led to routine on-site monitoring being
impossible to undertake for most trials. Within COVID-
19 trials, monitoring was still required but the use of
paper-based documents (including informed consent,
see Table 1) became a challenge. Hospitals mitigated
against cross contamination from paper-based docu-
ments by not allowing paper to leave COVID-19 areas
or delaying their release for a specific number of days. In
this paper, we report the experience of the United
Kingdom Clinical Research Collaboration (UKCRC)
Monitoring Task and Finish Group in undertaking mon-
itoring both within COVID-19 trials and non-COVID-
19 trials being conducted during the pandemic. Mem-
bers of this group were monitoring leads for nine clinical
trials units (CTUs). Some of the learning is specific to
COVID-19 trials, or to trials of similar infection/mode
of transmission, some to non-COVID-19 trials operating
during a pandemic and some ways of working could be
used as routine post the COVID-19 pandemic. Informed
consent is included as a specific issue within this paper,
as review of the process and documentation of informed
consent is often required within trial monitoring plans
(TMPs). The terms on-site monitoring, centralised
monitoring, remote monitoring and informed consent
are defined in Table 1.
Consent
In an infectious disease setting, the patient may have the
capacity to consent but there are practical limitations to
capturing written evidence of this. For example, a hard
copy of the patient information sheet and consent form
can enter the ward, but cannot leave the ward once
signed, due to the risk of infection transmission on
paper documents. Various solutions around consent
have been considered and incorporated into trials
Table 1 Definitions
On-site monitoring is performed at the investigator sites at which the
clinical trial is being conducted, via a physical visit by individuals from
the sponsor (and/or its representatives, for example monitors and other
CTU staff). It requires access to the medical records of trial participants
for the purposes of source data verification/review (SDV/SDR), to
confirm the accuracy of data transcription reported on the case report
form (CRF), to confirm accurate reporting of all relevant clinical
information (e.g. adverse events, concomitant meds), to confirm
compliance with the protocol and the principles of GCP and to verify
the existence of participants. On-site monitoring also usually includes
site file review, verifying investigational medicinal products (receipt, stor-
age, dispensing, accountability and destruction), review of facilities and
equipment and training of site staff. On-site monitoring may be pre-
planned (routine) or may occur when an issue is found at a site by cen-
tral or remote monitoring (triggered).
Centralised monitoring is performed in a location away from the
investigator site, and often at clinical trial unit/sponsor offices. It involves
an evaluation of accumulating data (or lack thereof), performed in a
timely manner, supported by appropriately qualified and trained persons
(e.g. data managers, statisticians, trial managers, data scientists). The aim
is to mitigate specific trial risks defined in the risk assessment document
which is completed before recruitment and continually reviewed during
the lifetime of the trial. Data are examined by site to identify trends,
outliers, anomalies, protocol deviations and inconsistencies. Concerns
raised by members of the sponsor/CTU trial team discovered during
their contact with the site are also taken into consideration. Centralised
monitoring may be the only monitoring (or it may lead to an on-site
monitoring visit). It complements and reduces the extent and/or fre-
quency of on-site monitoring and helps distinguish between reliable
data and potentially unreliable data ([1] section 5.18.3). Centralised moni-
toring does not require trial site staff input unless an issue is found.
Remote monitoring is evaluation performed by individuals from the
sponsor at a location remote from the trial site. It may include informed
consent forms (ICFs) being sent to the central office to enable a number
of checks to be performed with appropriate patient consent and data
protection issues addressed, accountability log collection, site self-
completed monitoring checklists or telephone/video monitoring calls. In
some instances, remote SDV/SDR may be considered but this is
dependent on sponsor procedures, site procedures and site capacity. Re-
mote SDV/SDR may be performed by the trial site providing pseudony-
mised source data to the monitor, the monitor having direct access to
the trial participant’s electronic medical records or using a video confer-
encing approach. Remote monitoring requires input from the trial site.
Informed consent is a process by which a subject voluntarily confirms
their willingness to participate in a particular trial, after having been
informed of all aspects of the trial that are relevant to the subject’s
decision to participate. Informed consent is usually documented by
means of a written dual signed (patient and person taking informed
consent) and dated informed consent form. Monitoring often includes
checking that informed consent was correctly taken.
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investigating treatments for COVID-19 as summarised
in Table 2.
During the development of COVID-19 trials, several
CTUs utilised early and ongoing communication with
the Health Research Authority (HRA) to ensure plan-
ning of the consent process was optimal and realistic.
These adaptions were required due to limited resource
at sites and various challenges associated with COVID-
19 ‘red zones’, conscious/unconscious patients and re-
stricted (no) face-to-face contact with relatives. There
are established procedures that can be borrowed from
entering adults lacking the capacity to consent [11] and
minors [12] onto a clinical trial without consent.
Some COVID-19 trial designs (platform trials includ-
ing more than one primary aim) were innovative in that
they required consideration of several options for taking
consent (Table 2).
Monitoring without on-site visit option
In the setting of a global pandemic, access to trial sites
for non-essential staff is likely to be restricted and
therefore on-site visits may not be possible. In the UK
COVID-19 pandemic, the HRA advised trial teams to
consider what monitoring was required immediately
as opposed to what could be delayed. As long as it did
not add to a site’s burden, the HRA allowed alternative
monitoring arrangements to be made without a proto-
col amendment (if site-level schedules were specified
in the protocol). The risk assessment and/or monitor-
ing plan may need to be adapted with the acceptance
of some risks which would under usual circumstances
be mitigated by on-site monitoring review. All file
notes, monitoring mitigations and SOP deviations
should be discussed with the relevant Quality Assur-
ance (QA) team, and Monitoring Visit Reports
(MVRs) must accurately state the reason why changes
occurred. Updated study risk assessments should also
be discussed with QA teams, chief investigators (CIs)
and sponsors. Critical data points should be risk
assessed for likelihood of error and whether such er-
rors could be detected via a centralised monitoring
method or simply accepted. Errors may also be picked
up without the need to see the source data and can be
checked by real-time review of data entered into the
electronic case report form (eCRF) by CTU staff and
where obvious errors are noted, or missing critical
data are identified, this can be clarified directly with
the trial site (routine data management). Where these
risks cannot be accepted or mitigated in this way, a re-
mote monitoring method is necessary which may in-
clude remote source data verification (SDV) or source
data review (SDR). Remote monitoring can be
achieved a number of ways but relies heavily on site
input and is, therefore, limited by site capacity. It may
be possible that sites, particularly those experienced in
early phase work, may be able to perform SDV within
their usual process and experience. We have experi-
ence of sites, taking on the SDV task in this way for
COVID-19 trials, utilising independent staff and a ro-
bust process. Given limited resources at site currently,
this option may be limited to COVID-19 trials rather
than non-COVID-19 trials but offers an option in a
post-COVID-19 era.
Direct access to site electronic health record (EHR)
provided to the monitor away from the site enables
monitoring with little site input. It can create issues
around confidentiality and it is only feasible where the
EHR was set up with such access in mind. Consideration
needs to be given to where access takes place, for ex-
ample an open plan office, public space or other loca-
tions where others who are not authorised could view
sensitive information. Host organisations and sponsors
(with input from their Caldicott Guardian if applicable)
need to provide explicit instructions on what can be
accessed where, and an agreement from the monitors
that this will be complied with. Access from home can
be acceptable, provided that there is somewhere private
that this can be done. The device through which EHR is
accessed must have adequate security, such as adequate
firewalls, secure log-in and passwords etc., and must not
be left unattended and accessible. The instructions
should not allow printing, emailing or downloading of
any records, or this should be disabled within the system
[13]. Our recent experience is that this has been possible
for one UK National Health Service (NHS) Trust. This
method is highly effective and does not cause an in-
creased burden for trial sites as monitors can access the
data and perform review without site staff input, other
than the site providing access and for addressing critical
issues at the end of the review.
Pseudonymised source documents have been provided
for a very small amount of data and trials. There is a
high burden for sites to redact source data and this
method is open to errors in redaction and copying. EMA
guidance states that documents monitored in this way
need to be rechecked on-site [10]. Hence, this would
only be possible if there were sufficient staff time at site
and only as a temporary measure.
Another remote monitoring approach is the use of
video conferencing where site staff use a secure confer-
encing platform and screen share the health record with
the monitor. Some trial sites are considering this option
where it is not possible to provide the monitor with dir-
ect access to the electronic health record. As site staff
will need to access the record and share their screen
during the whole review, this is a high burden to sites.
There is also anecdotal experience that some sites do
not allow the use of video conferencing due to data
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How consent is taken
eConsent
face-to-face
There is validated software, often linked to
data management capture tools, available
that can be downloaded onto a tablet for
patients to provide electronic consent.
Generic electronic signature products can
also be used.
Informed consent can be enhanced with
various features, e.g. video information,
call out boxes, pictures and consent flags
(dependent on the software solution).
A central record can be maintained by
those who require it, e.g. sponsor or CTU.
Sites have access to electronic record of
the informed consent form (ICF).
Sites can clean electronic devices
between use.
Solves the problem of moving paper
within infectious areas (red zones).
The approach is supported by the MHRA
and HRA [8].
Some evidence that eConsent improves
recruitment [9].
The software has cost implications for
sponsors.
The availability of electronic devices in
hospitals is limited or incurs a cost for
sites or sponsor to purchase. Storage and
charging need to be arranged.
The local team may not be familiar with
the software.
Those monitoring will also need to be




Interested participants are directed to a
trial website, which outlines the study and
provides the PIS. The interested participant
goes through simple screening questions
and those that pass are asked to provide
contact details. The CTU receives the
details and liaises with a clinician to call
the patient. If eligible, a video call is set up
with the clinician, where the PIS is
discussed in full, eligibility is taken and
consent is provided by the patient and
clinician. On verification of consent, an
email is sent to the participant which
holds a link to their consent form. The
clinician and CTU can access the consent
form via the secure website.
Trial consent can be taken anywhere and
the patient does not need to be co-
located with the clinician.
Site staff burden is reduced as the trial
has a central group of clinicians to liaise
with patients and take consent.
Patients are not required to leave their
homes during a pandemic so virus
transmission risk reduced.
Copies of the consent form are provided
by email link to patients, as a record of
patient consent.
Evidence of consent is available to
sponsor/CTU by electronic means via a
secure website.
Patients may not be familiar or
comfortable with sending contact details
via the trial website.
Patients may not be familiar with video
calls. Where patients do not have access
to the required technology, back up
measures should be considered so that
they are not excluded from the research
for this reason.
Additional training requirements to
conventional consent.
Physical examinations are not possible.
High-risk trials are likely to be unsuitable,
due to the virtual nature of the trial, or
additional steps to confirm eligibility via
patient records need to be implemented.
Need a process in place to verify the
participant is who they say they are—




Patients are provided with paper copies of
the written informed consent documents
on the ward. Patients/investigators sign
and date consent and a photo or scan is
taken of signed documents.
There are minimal cost implications,
unless hospital equipment needs to be
purchased.
Provision of consent is in line with the
usual process which local team are
familiar with.
Solves the problem of moving paper
within infectious areas as the paper
version can be processed or destroyed
(and documented) in accordance with
local policies.
Data protection considerations must be
considered. For example:
• Sites need to be compliant with their
data protection policies/GDPR/SOPs,
which does include photography.
• Emailing identifiable images to the
central office may need advance
consideration of data protection issues,
secure transfer and site training.
Sites need access to devices to be able to
take photographs.
Risk that signatures are not legible/visible
in photos/scans, there is a risk that the
photo is lost or deleted in error resulting
in a loss of evidence of consent.
Who takes the consent
Witness [10] A witness could be present at the time
the patient gives oral consent. The witness
then provides written proof of the
witnessing of oral consent in a non-
infected area.
There are no cost implications, a paper
copy of the written informed consent
document is maintained and available for
monitoring purposes.
Reliant on the availability of a witness at




The use of personal legal representatives is
a well-established method of consent for
use in certain situations. Some COVID-19
trials have made use of this due to pa-
tients requiring mechanical ventilation.
A relative or close friend is approached,
either in person or via telephone,
No cost implications. Paper copies of
written informed consent are available for
monitoring purposes.
Preferential even when the relative or
close friend was on the phone and the
clinician documents their consent and
the clinician signs the consent form.a
May be restricted to use only with
patients who lack the capacity to consent
due to the severity of their illness.
Family may be unsure of what the
participant’s wishes would be and may be
reluctant to provide consent on their behalf.
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protection concerns and NHS local policies; there is site
variation on which systems may be permitted (if any).
Monitoring by phone using a monitoring checklist has
previously been used and found useful but this method
is reliant on site capacity. Source documentation is not
specifically being reviewed (SDV is not possible), but the
discussion can provide the opportunity to identify con-
cerns and support the site.
Another option would be for questionnaires, site qual-
ity control checklists and essential documents to be
completed by the site and sent to the monitor. This
approach is limited, due to site capacity for completing
checklists and scanning and emailing documents. It has
previously been found useful for investigational medi-
cinal product (IMP) accountability and acceptable to
sites where pharmacy resource was not redeployed.
If one of the procedures outlined above is undertaken,
then consideration also needs to be given to the process
of triggering on-site monitoring visits. Where these visits
will not be possible, alternative actions should be out-
lined such as telephone contact with site staff to assess
compliance/issues and/or other types of remote moni-
toring activities as detailed above.
Table 3 gives more detail on phone and video confer-
ence remote monitoring.
For trials in setup where remote monitoring is planned
from the outset, this should be reflected in the protocol,
risk assessment and informed consent.
Monitoring without on-site or remote monitoring
option
When it is not possible to undertake monitoring on-site
and remote monitoring options are not possible, then fo-
cused risk-based monitoring may be considered. With
this method of monitoring, the sponsor should identify
the key risks involved with the trial and develop a cen-
tralised method of reviewing these risks. Primarily, the
focus should be on patient safety, primary outcome
measure data and any other data considered critical. An
example from one CTU was to focus on data relating to
patient safety. Data relating to adverse events and proto-
col deviations were collated and reviewed at monthly




provided with the relevant information
sheets and asked if they feel the
participant would consent to being
included in the research. If they feel the
participant would be happy to take part,
then a personal legal representative
consent form is completed. In the context
of COVID-19, these conversations should
take place outside the infection area (red
zone).
If the participant regains capacity to
consent at a later date, they are provided
with the relevant information sheets and
are asked to complete the consent forms
indicating that they are happy for data to





For patients who are critically ill and are
unable to provide consent and there is
either no-one suitable by virtue of their re-
lationship to the patient or a suitable per-
son does not wish to or is unavailable to
act as the legal representative, a profes-
sional legal representative (ProfLR) may be
approached. This is a medical professional
caring for the patient who is unconnected
to the trial. If they have no medical or eth-
ical objections to the participant taking
part, then a ProfLR consent form is com-
pleted. Again, in the context of COVID-19
research, all paperwork should be com-
pleted and stored outside the infection
area (red zone).
If the patient regains capacity to consent,
they will be asked to complete consent to
continue as detailed above.
No cost implications. Paper copies of
written informed consent are available for
monitoring purposes.
Restricted to use only with patients who
lack the capacity to consent due to the
severity of their illness.
aIn Scotland, the ‘guardian or welfare attorney’ is the first preference, prior to the nearest relative
Legend: ‘electronic methods for seeking informed consent’ and ‘eConsent’ refer to the use of any electronic media to convey information and to see and/or
document consent via an electronic device
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Trial Management Group (TMG) meetings where the
frequency and type of events as well as the quality of the
data submitted were considered. Anything which raised
concern with the TMG triggered a telephone call with
the site principal investigator, and further investigation
was carried out if necessary. A Data Monitoring Com-
mittee (DMC) was also convened monthly with the aim
of independently reviewing safety data. This method re-
quires timely submission of data from the site so emer-
ging triggers can be quickly identified.
Note that monitoring of all studies during the
COVID-19 pandemic is likely to lead to deviations from
and updates to the monitoring plan due to changing
conditions.
Minimising data
Due to the potential for placing an increased burden on
participating sites that some remote monitoring
methods may pose, coupled with the need to be
confident in the completeness and accuracy of data,
one important consideration is the quantity and com-
plexity of the data requested.
The collection of non-essential data has long been
known to increase the burden on both participating sites
and sponsors, and this is now starting to be quantified.
Recent data from Fougerou-Leurent et al. [14] suggest
that only 13% of the data collected are critical data items
and Crowley et al. [15] found 5% of items were for the
primary outcome of the trial.
If the data collected can be reduced to that which
is considered critical, this will reduce the burden on
sites for CRF completion and sponsors for monitor-
ing. The reduction in data collection also has wide-
reaching benefits for the CTU including simplified
and more rapid CRF and database development, more
efficient data management and statistical analysis and,
most pertinent to this review, fewer data points for
which monitoring is required. RECOVERY-RS re-
duced the data collection to be as simple as possible,
with agreement between the Trial Management
Group (including the trial statistician), programming
team and QA team.
If the COVID-19 pandemic can bring one benefit to
clinical research in the long-term, minimising data col-
lection would be a wide-reaching, mutually beneficial
process improvement.
Although the requirement for data minimisation is
well established and embedded within the Data Protec-
tion Act, 2018, the pandemic has encouraged trial devel-
opment teams to consider data minimisation far more
than they may have done previously. This was largely
due to the clinical impact of the pandemic, when site
Table 3 Working example of monitoring using phone and video conferencing
Action
item
Aim Monitor’s actions Comments
1 Decrease the requirement for site-level
monitoring; by implementing alterna
tive monitoring mitigations
TC or email site staff (PI team) to ask if/when
they are available for a TC or VC in place of an
on-site monitoring visit and what data could be
shared with the monitor ahead of this virtual
meeting.
Use video conferencing if the site has the IT
access. If not, then a TC. Ensure monitors have
the flexibility to meet with site staff when it is
convenient for the sites.
2 Prioritise patient safety, outstanding
site actions and data integrity of the
study primary endpoint for remote
monitoring
Develop a template tracker to ensure the
minimum safety and primary endpoint data are
discussed in the TC/VC.
Put the questions in priority order for the TC/VC.
3 Give the site as much time as possible
to prepare*
Request appropriate documents ahead of the
meeting—keep this to a critical minimum.
This could include investigator site files (ISFs);
delegation logs; primary endpoint
pseudonymised source data.
4 Conduct a successful site TC/VC. Review appropriate documents ahead of the
meeting.
In line with preparation for all monitoring visit
types
5 Prioritise the discussion with the site in
case the call is cut short by technical
problems or a local emergency.
Use the template tracker completed with all
actions required of the site and prioritise the TC/
VC discussion accordingly.
Discuss the timing of the next remote visit
6 Manage any resulting issues Escalate any unreported SAEs, missing visits,
major deviations impact on patient safety/data
integrity of missing visits.
Quality, CI, PI, stats and sponsor may need to be
consulted.
Update study risk assessment with site-specific is-
sues and/or availability during COVID-19 out-
break. Consider what appropriate actions, if
necessary, should be undertaken
7 Complete the monitoring visit report
(MVR) and site f/up letter.
As normal. No comments.
TC teleconference, VC video conference, CI chief investigator, PI principal investigator, SAE serious adverse event
*Note that for COVID-19 studies, sites should be informed of and agree to the minimum data they will be asked to supply for remote monitoring,
where employed
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staff were under extreme pressure, so minimising data as
much as possible was essential.
Altered data collection and retention
Limiting paper contamination within COVID-19 areas,
as well as clinical trial burden due to the reduced staff
resource at participating sites, has required other trial
management adaptations. Examples from COVID-19 tri-
als have included the completion of validated patient-
reported outcome measures (PROMs) tools via the
phone rather than patients completing the forms dir-
ectly. This could be done by research staff at sites, or by
CTU staff if patients have given consent for this.
COVID-19 trials also presented additional consider-
ation when discussing where and how patients were
identified and confirmed as COVID-19 positive. This
was partially due to the rapidly evolving national situ-
ation around screening, availability of screening and
false-negative rates and also how patients were managed
once eligibility was confirmed as patients not requiring
clinical care were discouraged from attending hospital
settings. These issues present challenges for monitoring.
At a sponsor or central level, trial master files (TMFs)
are often paper based. With many CTU staff moving to
a home-based working arrangement, mitigations have
needed to be made. In some instances, this has involved
consideration and implementation of electronic TMF.
Site setup changes
Although some CTUs have previously carried out site
initiation visits (SIVs) using video conferencing facilities
instead of on-site visits [16], during the COVID-19 pan-
demic, this has become the only solution for site initi-
ation. The basic structure is similar to face-to-face SIVs
with a comprehensive slide set, live presentations by the
clinical and trial management teams, and an opportunity
for questions. The familiar structure enables a trial team
to develop materials in an established way, but then
adapt the delivery to suit the current environment. Run-
ning sessions for multiple sites at a time also enables
sites to benefit from shared best practice learned from
other participating sites attending at the same time.
In the RECOVERY-RS trial, a large site-setup team
was established, and SIVs were conducted every weekday
at three time slots per day. Time slots were advertised to
sites with booking details. This was cost- and time-
efficient for the trial team and for site staff and enabled
multiple sites to receive a SIV simultaneously. It also en-
abled multiple site staff to attend different SIV slots,
from numerous locations, fitting in with workload and
availability. With clear guidance on the meeting conduct,
a separate member of the team managing the video con-
ferencing admin, and questions posted via the ‘chat’
function, meetings ran smoothly and replicated a face-
to-face meeting as much as possible.
Risk-proportionate approaches should always be used
to ensure oversight of adequate experience and training
of site staff, and the current situation can provide an op-
portunity to tailor the oversight more specifically to each
individual trial. It may not always be necessary to collect
curriculum vitae (CVs) and GCP certificates for all (or
any) site staff, if the principal investigator (PI) or R&D
department can confirm they are held on site. The PI is
responsible for their research team being trained and ex-
perienced in their role. Equally, a hierarchy of study-
specific training requirements may be implemented to
request a core set of study training to be completed and
signed off by the PI only, with PI oversight to confirm
site staff have appropriate training to perform their role
within the trial. Websites can be a useful tool to provide
and record training and also act as a document reposi-
tory, alongside a website’s traditional remit of trial pro-
motion. Training materials can be available for sites to
access electronically, with the ability to ‘sign off’ training
modules online removing the need for paper copies,
simultaneously providing central oversight of each site’s
training status (and potentially removing the need for a
separate delegation log). This facilitates local site setup,
enabling work to be done at individually convenient
times, without the need for printing facilities or transfer
of paperwork.
Speed of trial development
Many CTUs redirected resource to COVID-19 trial devel-
opment and staff have worked at pace, contributing many
hours in a short time, collaborating with many individuals
and organisations (pharma, laboratories, clinicians, gov-
ernment) to pull together and fast track trial ideas into
solid trial proposals, creating protocols in just a few weeks.
Throughout the process, the MHRA and HRA have been
available for early discussion, prior to submission, to en-
sure approvals can be swift following submission. In most
cases, MHRA and HRA approvals have been issued in a
matter of days including national holidays. There have
also been additional steps that COVID-19 trials have
needed to navigate, the primary one being Urgent Public
Health (UPH) priority approval which ensured sites priori-
tised work on COVID-19 trials with high priority ques-
tions as deemed by the government. Due to the
overwhelming demand for UPH approval, their review
was sometimes conducted in parallel with MHRA and
HRA review in order to maintain trial setup momentum.
Due to the speed of setup of COVID-19 studies, moni-
tors have been required to fast track trial risk assess-
ments and the subsequent trial monitoring plans,
including considerations of mitigations due to site access
restrictions and minimised site resource requirements.
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There was little precedence for this in the UK at the
time, meaning many sponsors were ‘thinking on their
feet’ to provide pragmatic solutions to emerging and
evolving challenges.
Early phase trials have been required to review Safety
Review Committee (SRC) processes, as usual practice is
complete SDV of the data being discussed which inform
dose escalations. Trial-specific mitigations have been con-
sidered (e.g. site performing SDV as described previously).
Whilst there have been significant achievements with
developing complex trials in an expedited manner, there
are some less positive aspects of the process. Accelerated
protocol development and trial setup processes have re-
quired a substantial resource allocation, which in most
cases has been delivered by experienced staff working
evenings and weekends for prolonged periods. Similarly,
once approved, the trials have required frequent amend-
ment to account for the changing pandemic landscape,
emerging safety information and differing processes
across healthcare settings. The impact of these on the
risk assessment and monitoring plans makes this chal-
lenging for sponsors, CTUs and sites to manage.
Impact on non-COVID-19 portfolio
Many sponsors and sites suspended recruitment into trials
at the start of the pandemic, and sites participating in ac-
tively recruiting trials decided if patients already recruited
were able to continue treatment and follow-up. A risk-
based approach was implemented and protocol processes
were reviewed. Examples include clinician/patient phone
calls rather than hospital clinic visits, transfer of patient care
to alternative healthcare providers, provision of investiga-
tional medicinal product (IMP) to patients at home and use
of validated safe-boxes for the return of samples via post.
These actions have required changes to central monitoring
of data, for example a metric alarm threshold for deviations
would need to be increased. Often, SDV of data has been
stopped with monitoring defaulting to central and remote
monitoring, but this is expected to recommence as condi-
tions permit.
Lastly, as sponsors and CTUs plan for trial restart, they
should consider COVID-19 impact trial viability assess-
ments which address if/how the trial population, interven-
tions and outcomes have been impacted to inform if trials
are able to re-open or not, and whether any changes are
required. Early and open engagement with the trial site
staff and the R&D office is important. Trial opening and
change decisions may require trial risk assessments and
the data monitoring plans to be updated. Sites need to
commit to the necessary monitoring, and if the site can-
not, then consideration may need to be given to keeping
the site on hold to recruitment; this capacity review will
often form part of the site-level risk assessment, which are
likely to be required prior to re-opening [17].
Discussion
With the arrival of COVID-19 in the UK and the
need for COVID-19 trials to be rapidly created and
open to recruitment, monitoring aspects of trials had
to develop and adapt at speed. The announcements
on clinical trial conduct from the UK Government
[18], HRA [19] and EMA [10] were helpful though
not exhaustive. CTU staff needed to interpret the
guidance and make decisions for their own CTUs.
Changes were made to the informed consent process,
what data were collected and the method of setting
up sites. Risks were considered within the new cli-
mate to enable monitoring without site visits or un-
due burden to the sites. Many of these changes could
continue. For all future trials, sites could access the
training at a time of their convenience and this could
be recorded electronically, with the PI notified so that
they can delegate tasks in an informed manner. For
trials with many sites, site initiation visits could be
done at regular times with personnel joining when
they are able. Datasets should be minimised and pa-
tients could use on-line consent (eConsent). With
monitoring, it could be recommended that we recon-
sider our over-reliance on on-site monitoring and
more research effort could be focused on optimising
central monitoring so that the site burden is mini-
mised. As electronic patient record systems evolve, if
sites could ensure that their electronic patient record
systems are able to offer remote access to trial staff,
restricted to specific trial participants, monitoring
would be enabled. If this is not possible in the short
term, site organisational risk assessments could take
place to allow access to be given in the interim with
data protection principles upheld.
The speed and efficiency of COVID-19 trial setup from
the CTUs was complemented by the matched speed of as-
sessment from the HRA, MHRA and UPH. It should be
noted however that the intense speed of setup came at the
cost of CTU staff working very intense hours, and mul-
tiple protocol and document amendments which is ineffi-
cient and undesirable outside of the pandemic situation.
Some efficiency improvements could continue; examples
include efficient document creation using learnings from
COVID-19 trials (e.g. consent options), minimising data
collection, development of database library documents
and better understanding of SIV options.
Our paper only reports the experience from nine
UKCRC registered CTUs and only on the monitoring as-
pect of trial conduct. The differences for non-CTIMP
and Scottish regulations have not always been explicitly
stated. However, we hope it helps others setting up
COVID-19 or managing non-COVID trials during the
pandemic and gives some material for consideration of
changes to the conduct of clinical trials more broadly.
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